SCCM is performing maintenance on its websites. For the best browsing experience, please use Microsoft Edge or Safari. Those using Chrome or Firefox may experience access issues at this time.

Category: Pharmacology

Category Search

visual bubble
visual bubble
visual bubble
visual bubble

Consideration of Severe Coronavirus Disease 2019 As Viral Sepsis and Potential Use of Immune Checkpoint Inhibitors

From Critical Care Explorations. Supportive treatment and immunomodulators have a critical place in the treatment of severe patients until effective antivirals are developed. Interleukin-6 antagonists, one of the immunomodulating agents, appears to be effective in the treatment of cytokine storm, but some patients continue to have severe lymphopenia and immunosuppression.


Which patients should be treated with remdesivir and when should it be initiated?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on July 8th, 2020.


Can you give an update on the current literature on using steroids in the treatment of COVID-19? How are you using this literature in your practice?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on July 8th, 2020.


What data support the use of convalescent plasma? Do you have experience with it? Which patients should be treated with it?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on July 8th, 2020.


Alternative Analgesic and Sedative Agents in the Setting of Drug Shortages during the COVID19 Pandemic

This resources detail how to manage drug shortages for alternative analgesics and sedagent agents. This is SCCM curated COVID-19 microlearning content.


COVID-19 Pharmacology Debates: Steroid and Antiviral Use in COVID-19 Patients

ASHP and the SCCM teamed up in their second series of therapeutic debates in the management of COVID-19. In the first debate, the content matter experts reviewed the latest literature and debate the use of steroids for treatment of COVID-19.


COVID-19 Pharmacology Debates: Management of Delirium, Pain and Sedation

The Society of Critical Care Medicine (SCCM) and the American Society of Health-System Pharmacists (ASHP) in their third series of therapeutic debates in the management of COVID-19.


Renin-Angiotensin System and COVID-19

This presentation is a review of the renin-angiostensin System and COVID-19. This is SCCM curated COVID-19 microlearning content.


Antiviral Dosing Modification for Coronavirus Disease 2019–Infected Patients Receiving Extracorporeal Therapy

From Critical Care Explorations. In this study, the authors gathered available published resources including physicochemical and pharmacokinetic properties and suggest antiviral drug dosing adaptation for coronavirus disease 2019–infected critically ill patients receiving extracorporeal therapy.


Physiologic Response to Angiotensin II Treatment for Coronavirus Disease 2019–Induced Vasodilatory Shock: A Retrospective Matched Cohort Study

From Critical Care Explorations. In this study, the authors found that angiotensin-II treatment for coronavirus disease 2019–induced distributive shock was associated with rapid improvement in multiple physiologic indices and that angiotensin-II in coronavirus disease 2019–induced shock warrants further study.


Vitamin Treatment and Renin-Angiotensin System Inhibition in Patients with COVID-19

During this 1-hour activity expert faculty from the American Society of Health-System Pharmacists and the Society of Critical Care Medicine discussed the use of vitamins as adjunctive treatment in patients with COVID-19 as well as the role of Renin-Angiotensin System Inhibition in COVID-19 patients.


Does literature on the peripheral vascular administration of vasoactive drugs apply to children as well as adults?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 9, 2020.


Are you using convalescent plasma in your practice?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on September 9, 2020.


What is your typical medication regimen for COVID-19?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on October 14, 2020.


If a patient has had COVID-19 for 3 weeks and is still short of breath and fatigued and has a lot of ground-glass opacities on radiograph, should this patient receive steroids?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on October 14, 2020.


Would you use remdesivir or steroids as early as admittance to the emergency department? Do you advocate their use?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on November 4, 2020.


Are pharmacists well versed in which COVID-19 drugs to use?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on November 4, 2020.


Do you recommend calling pharmacy or infectious diseases for patients admitted to the ward with a positive COVID-19 test and some COVID-19 symptoms?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on November 4, 2020.


For a stable patient on the ward who needs 2 to 4 liters of oxygen, is hemodynamically stable, and does not seem to be deteriorating, would you start a medication such as remdesivir or steroids or would you wait until the patient’s condition starts to det

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on November 4, 2020.


After a patient has tested positive for COVID-19, when is the most appropriate time to administer remdesivir to maximize its effectiveness?

Questions from social media, blogs and the various discussion forums, including the new SCCM COVID-19 Discussion Group, were answered. This microlearning content was taken from the COVID-19 Critical Care for Non-ICU Clinicians: Expert Panel Series held on November 4, 2020.